Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 1,258 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 1,258 shares of Beta Bionics stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $15.01, for a total value of $18,882.58. Following the completion of the transaction, the insider owned 129,354 shares of the company’s stock, valued at approximately $1,941,603.54. This represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Thursday, June 4th, Mark Hopman sold 275 shares of Beta Bionics stock. The shares were sold at an average price of $12.31, for a total value of $3,385.25.
• On Tuesday, June 2nd, Mark Hopman sold 5,329 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total transaction of $67,198.69.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $15.91 on Friday. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a 50-day simple moving average of $12.05 and a two-hundred day simple moving average of $15.57. The company has a market cap of $708.95 million, a P/E ratio of -10.54 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, equities research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Institutional Investors Weigh In On Beta Bionics

Institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC lifted its stake in Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after acquiring an additional 240,000 shares during the period. Eversept Partners LP raised its holdings in shares of Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Quantinno Capital Management LP lifted its position in Beta Bionics by 112.9% during the first quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock valued at $680,000 after purchasing an additional 35,996 shares during the period. Lazard Asset Management LLC acquired a new position in Beta Bionics during the first quarter valued at $720,000. Finally, Granahan Investment Management LLC lifted its position in Beta Bionics by 104.9% during the first quarter. Granahan Investment Management LLC now owns 248,449 shares of the company’s stock valued at $2,489,000 after purchasing an additional 127,203 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BBNX. Bank of America lowered their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Stifel Nicolaus cut their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. The Goldman Sachs Group reduced their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.